J-Y Pierga

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

M.E. Dujaric, Véronique Scott, O. Tembo et al. · British Journal of Cancer · 2013 · 92 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

Véronique Dièras, J.M. Extra, Éric Bellissant et al. · Journal of Clinical Oncology · 1996 · 69 citations

Medicine, Oncology, Pharmacology +15

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

Anne Vincent‐Salomon, J-Y Pierga, J Couturier et al. · British Journal of Cancer · 2007 · 61 citations · Full text

Medicine, Oncology, Pathology +15

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

Xavier Pivot, Gilles Romieu, Hervé Bonnefoi et al. · Cancer Research · 2012 · 37 citations

Medicine, Oncology, Pharmacotherapy +17

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

Thomas Bachelot, Gilles Romieu, Mario Campone et al. · Journal of Clinical Oncology · 2011 · 35 citations

Medicine, Oncology, Pharmacotherapy +17